ERFSF Stock Chart & Stats
$80.52
--
Market closed
$80.52
--
Day’s Range― - ―
52-Week Range$64.95 - $92.97
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.34K
Market Cap
$15.22B
Enterprise Value$17.48B
Total Cash (Recent Filing)$618.00M
Total Debt (Recent Filing)$5.47B
Price to Earnings (P/E)25.7
Beta0.35
Next Earnings
Mar 02, 2027EPS Estimate
1.81Next Dividend Ex-DateN/A
Dividend Yield1%
Share Statistics
EPS (TTM)3.00
Shares Outstanding176,000,000
10 Day Avg. Volume5,280
30 Day Avg. Volume2,341
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.17
Price to Sales (P/S)1.54
P/FCF Ratio20.99
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit19.77
Enterprise Value/Ebitda11.73
Forecast
1Y Price Target
$73.35Price Target Upside-8.90% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)4.48
Revenue Forecast (FY)$8.43B
Bulls Say, Bears Say
Bulls Say
Diversified Global Laboratory PlatformEurofins operates across several regulated testing and scientific-services markets rather than relying on one end market. This breadth can support resilience through differing customer cycles, while its global laboratory network and broad test menu may deepen client relationships and enable cross-selling over the next several quarters.
Strong Recent Revenue ExpansionThe sharp 2025 revenue increase indicates stronger demand, expanded activity, or successful growth initiatives after a less consistent prior period. If retained, higher scale can improve operating leverage, broaden customer reach, and provide a stronger base for investment across Eurofins’ testing network.
Positive Operating Cash GenerationSubstantial positive operating cash flow demonstrates that Eurofins’ laboratory-services model is producing cash from operations, supporting reinvestment, debt service, and ongoing customer capacity. This provides a meaningful financial foundation even though free-cash-flow conversion weakened during 2025.
Bears Say
Material Leverage IncreaseThe steep increase in debt relative to equity materially reduces balance-sheet flexibility and makes the company more sensitive to weaker operating performance. Higher leverage can raise refinancing and interest-burden risk, potentially limiting acquisitions, investment, or other capital-allocation options.
Weaker Free-cash-flow ConversionAlthough operations remained cash generative, lower free cash flow and weaker conversion of earnings indicate that more cash was absorbed by capital spending or working capital. Sustained softness could constrain deleveraging and reduce internally funded capacity for laboratory expansion and acquisitions.
Margin Compression And VolatilityThe long-term decline in net margin and unusually low 2025 gross margin create uncertainty about the durability and quality of earnings. Persistent cost pressure or structural changes in the revenue mix could weaken profit conversion even if revenue growth remains strong.
Eurofins Scientific News
ERFSF FAQ
What was Eurofins Scientific’s price range in the past 12 months?
Eurofins Scientific lowest stock price was $64.95 and its highest was $92.97 in the past 12 months.
What is Eurofins Scientific’s market cap?
Eurofins Scientific’s market cap is $15.22B.
When is Eurofins Scientific’s upcoming earnings report date?
Eurofins Scientific’s upcoming earnings report date is Mar 02, 2027 which is in 141 days.
How were Eurofins Scientific’s earnings last quarter?
Eurofins Scientific released its earnings results on Jul 23, 2026. The company reported $2.349 earnings per share for the quarter, beating the consensus estimate of $2.147 by $0.202.
Is Eurofins Scientific overvalued?
According to Wall Street analysts Eurofins Scientific’s price is currently Overvalued.
Does Eurofins Scientific pay dividends?
Eurofins Scientific pays a Annually dividend of $0.842 which represents an annual dividend yield of 1%. See more information on Eurofins Scientific dividends here
What is Eurofins Scientific’s EPS estimate?
Eurofins Scientific’s EPS estimate is 1.81.
How many shares outstanding does Eurofins Scientific have?
Eurofins Scientific has 176,000,000 shares outstanding.
What happened to Eurofins Scientific’s price movement after its last earnings report?
Eurofins Scientific reported an EPS of $2.349 in its last earnings report, beating expectations of $2.147. Following the earnings report the stock price went down -8.132%.
Which hedge fund is a major shareholder of Eurofins Scientific?
Currently, no hedge funds are holding shares in ERFSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
ERFSF Stock 12 Month Forecast
Average Price Target
$73.35
▼(-8.90% Downside)
Technical Analysis
Ownership Overview
37.62% Insiders
10.24% Mutual Funds
― Other Institutional Investors
42.85% Public Companies and
Individual Investors








